Every year nine million people are diagnosed with tuberculosis, every day over 13,400 people are infected with AIDs, and every thirty seconds malaria kills a child. For most of the world, critical medications that treat these deadly diseases are scarce, costly, and growing obsolete, as access to first-line drugs remains out of reach and resistance rates rise. Rather than focusing research and development on creating affordable medicines for these deadly global diseases, pharmaceutical companies instead invest in commercially lucrative products for more affluent customers.
Nicole Hassoun argues that everyone has a human right to health and to access to essential medicines, and she proposes the Global Health Impact (global-health-impact.org/new) system as a means to guarantee those rights. Her proposal directly addresses the pharmaceutical industry's role: it rates pharmaceutical companies based on their medicines' impact on improving global health, rewarding highly-rated medicines with a Global Health Impact label.
Global Health Impact has three parts. The first makes the case for a human right to health and specifically access to essential medicines. Hassoun defends the argument against recent criticism of these proposed rights. The second section develops the Global Health Impact proposal in detail. The final section explores the proposal's potential applications and effects, considering the empirical evidence that supports it and comparing it to similar ethical labels. Through a thoughtful and interdisciplinary approach to creating new labeling, investment, and licensing strategies, Global Health Impact demands an unwavering commitment to global justice and corporate responsibility.
Nicole Hassoun here makes a philosophical argument for health, and access to essential medicines, as essential human rights, and she proposes the Global Health Impact system as a way to ensure those rights. She reports how life-saving medicines are inaccessible and costly for the global poor, and that rather than focusing on treatments for critical, deadly global health problems, pharmaceutical companies instead invest in more profitable drugs. To address this problem, Hassoun's proposal will rate pharmaceutical companies based on their medicines' impact on the improvement of global health, and will reward highly-rated medicines with a Global Health Impact label.
This is a timely book on an important topic. It makes a significant contribution to the debate on ethics in global health by focusing on measuring the global health impact of different drugs, and the companies that produce them. Her claims are bold and well-argued.
